The Secondary Prevention of Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke "CE"

Recruiting

Phase 3 Results N/A

Update History

23 Jan '15
Trial name was updated.
New
The Secondary Prevention of Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke
The Summary of Purpose was updated.
New
The Secondary Prevention of patients with an initial cardioembolic stroke associated with nonvalvular atrial fibrillation.
Old
Hirudin preventive effect on cardioembolic stroke.
The description was updated.
New
For the patients with stroke associated with atrial fibrillation,the guidelines recommend warfarin as the secondary prevention,but it's disadvantages such as the narrow safety scope,high bleeding risk hinder it's utilization in clinical.We divide our trial into two groups, the experimental group is aspirin plus Hirudin,the control group is warfarin.We aim at comparing two groups'efficacy and safety difference in secondary prevention of atrial fibrillation combined stroke.
Old
The efficacy and safety of Hirudin in combination with aspirin to prevent recurrence of cardioembolic stroke patients with non-valvular atrial fibrillation.
The eligibility criteria were updated.
New
Inclusion Criteria: - Age 18 years or older. - Stable condition within 14 days of oneset,Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke - Diagnosis need to conform to the Cardioembolic Stroke about clinical and neuroimaging and laboratory examination requirements. Exclusion Criteria: - Mitral stenosis or previous valvular heart surgery - Admission for acute coronary syndrome or percutaneous coronary intervention within 30 days - Active infective endocarditis - Purpura disease or blood coagulation disorder - Active bleeding or bleeding tendency - History of intracranial hemorrhage or other serious bleeding events - Confirmed with peptic ulcer disease within 30 days - Esophageal varices - Major surgical procedure or trauma in the previous 30 days - Persistent blood pressure 180/100 mm Hg or greater with or without antihypertensive treatment - Requirement for chronic anticoagulant treatment for disorders other than atrial fibrillation - Severe liver and kidney function - Allergy for warfarin, aspirin and hirudin - Child bearing potential, pregnancy, or lactation
Old
Inclusion Criteria: - age at 18 years of age and above. - stable condition within 14 days of oneset, patients with nonvalvular AF cardiac stroke signed informed consent. - diagnosis need to conform to the cardiac stroke about clinical and neuroimaging and laboratory examination requirements, and rule out other possible causes. Exclusion Criteria: - Purpura disease or clotting disorders - Active bleeding or bleeding tendency - A history of intracranial hemorrhage or other serious bleeding events - Planned major surgery, or within 30 days of a major surgery and severe injury - Have severe liver and kidney dysfunction - Warfarin, aspirin and hirudin allergy - Pregnant or lactating women
A location was updated in Xi'an.
New
The overall status was updated to "Recruiting" at Xijing Hospital.